REA Group (ASX: REA): A Digital Infrastructure Powerhouse
REA Group is not a cyclical advertising or media business but a durable digital infrastructure monopoly at the centre of Australia’s property economy, monetising the country’s most valuable consumer intent. The market’s focus on listings cycles, rates, and short‑term sentiment misses the point: REA’s core engine is yield, its moat is data, and its next phase of growth will be driven by AI‑led personalisation, deeper monetisation, and an expanding financial services ecosystem.
Carnegie Clean Energy (ASX: CCE): Operational Milestone Tests Whether CCE Can Break Its Downtrend
Carnegie Clean Energy (ASX: CCE) is advancing CETO wave-energy deployment and MoorPower commercialisation, supported by grants and $2.5 million placement. While October’s Spain deployment could be a catalyst, CCE remains a volatile, pre-commercial stock facing execution, funding and dilution risks.
REA Group (ASX: REA): Earnings Strengthen as AI Moves Centre Stage, but India Exit Reshapes the Growth Story
REA Group is reshaping its growth strategy through AI-powered property search, financial services and new agent tools. Stronger FY26 earnings supported the shift, while the planned sale of Housing.com marks a move away from direct Indian operations toward a more focused investment approach.
.webp&w=828&q=75)
Titomic (ASX: TTT): US Air Force Contract Win Follows $16.5 Million Capital Raise
Titomic (ASX: TTT) shares rallied after a US$5 million Air Force contract, following a $16.5 million placement. The advanced manufacturer, still loss-making, is progressing a US redomiciliation while shares test key support with a potential trendline breakout ahead.
EchoIQ (ASX: EIQ) Crisis Decoded: Regulatory Setback, Not Financial Collapse
EchoIQ shares plunged 60% after the FDA issued an NSE notice blocking its heart-failure AI product from the US market. Despite panic selling, strong cash reserves, an active second product, and a management options grant suggest this is a regulatory setback, not a financial collapse.
HeraMED (ASX: HMD)'s Lee Health Deal: A Small Contract with a Much Bigger US Ambition
HeraMED (ASX: HMD) launched a US$317,200 commercial deployment of its HeraCARE maternity platform at Lee Health, Florida, following a successful pilot. The deal, integrated with Epic EMR, is scalable and serves as a reference case for expanding US hospital partnerships, Philips channels, and rural healthcare programs.